Breadcrumb Home Business activities 麻豆社 BioCapital 麻豆社 BioCapital Portfolio River Vision River Vision Developed a biologic to treat the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness. Relateret nyheder om River Vision 8 May 2017 Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease 9 September 2016 River Vision Announces Receipt of Breakthrough Designation from US FDA 麻豆社 BioCapital Invested 2012 Acquired by Horizon in 2017 Location New York, USA
